Sepsis-S

• Sepsis, a life-threatening response to infection while AMR-the ability of microbes to resist the effects of medication, present a complex and intertwined threat to patient outcomes, healthcare systems, and public health on a global scale. Despite advances in medical science, sepsis continues to be a leading cause of morbidity and mortality worldwide. Sepsis accounts for 20% global mortality annually.
•   Overuse and misuse of antibiotics in healthcare and agriculture have accelerated the development of resistant strains of bacteria, rendering once-effective treatments ineffective. The rise of multidrug-resistant pathogens limits treatment options, prolongs illnesses, increases healthcare costs, and poses a grave risk to patient safety.

Interconnected Challenge-Sepsis Managements & AMR

• The convergence of sepsis and AMR compounds the complexity of infectious disease management. Sepsis often necessitates the rapid administration of antibiotics, and the prevalence of AMR compromises the efficacy of these treatments. 
• This synergy not only jeopardizes patient outcomes but also places an immense burden on healthcare systems, exacerbating the challenge of delivering timely and effective care.

 Lack of accessible & affordable surveillance tools especially in LMICs is major bottleneck in solving these problems. Coordinated efforts innovative solutions to safeguard patient well-being, uphold the efficacy of healthcare interventions, and fortify global public health resilience are needed.

Technology brief of Sepsis-S:
Sepsis presents a critical global challenge, particularly in regions with limited resources, demanding urgent attention for the precise detection of sepsis. Each year, sepsis affects 50 million individuals worldwide, resulting in 11 million fatalities. Sepsis-related neonatal deaths are taking place in rural India where more than 60% of the Indian population lives. The case fatality rate of sepsis among neonates ranges between 25% to 65% in India and most of the cases are from villages and remote areas where inadequate medical infrastructure is there.
Introducing a point-of-care (PoC) device for sepsis could revolutionize multiple industries and benefit society immensely. We have our ground-breaking Sepsis assay, Sepsis-S, a cutting-edge, digitally-enabled PoC test designed to swiftly detect sepsis. This assay fills a crucial gap by addressing the significant issue of timely sepsis detection, thereby improving sepsis management and patient outcomes. Its simplicity allows testing to be conducted at the patient's bed-side with minimal training, making it ideal for low-resource settings where it has the potential to save millions of lives. Moreover, real-time data transmission to healthcare providers ensures prompt and informed decision-making.
Sepsis-S, an innovative electrochemical assay that transforms your smartphone into a portable laboratory, offering easy storage and sharing of data from any location to doctors for quick consultations. It’s crafted especially for low resource settings and well suited to work in any climatic conditions. Sepsis-S operates on the principle of electrochemical sensing, leveraging the specific interactions between sepsis biomarkers and electroactive molecules immobilized on the sensor surface. When the patient sample, typically blood, is added to the sensor, the target biomarkers bind to the sensor surface, initiating electrochemical reactions. These reactions generate measurable electrical signals, which are then translated into quantitative data indicative of the presence and concentration of sepsis-causing biomarkers.

Sepsis-S embodies cutting-edge features tailored to address critical healthcare needs:

1. Point of care detection with minimal training required to perform the test. 
2. Rapid and precise detection within minutes (<30min), enabling prompt medical intervention. 
3. Less amount of sample is needed for testing.
4. Digitally enabled (Ai/ML based predictive modelling) for real-time information sharing and analysis. It reduces the time of analysis with better decision making for doctors, a crucial feature to reduce burden on healthcare systems, especially needed for resource poor regions.
5. Cloud server data storage and AI modelling for data analysis and report-generation.

In addition to its current capabilities, future iterations of Sepsis-S will incorporate pathogen and AMR gene detection modules to combat Antimicrobial Resistance (AMR) effectively. By expanding its functionality, Sepsis-S aims to further enhance sepsis management strategies and contribute to improved patient outcomes globally.

Our solution serves a larger population in LMICS. Its a Point-of-Care (PoC) solution for Sepsis screening and AMR surveillance, that extends critical public good  by ensuring broader healthcare access, particularly for underserved populations in LMICs. This inclusive approach addresses the deprivation of basic healthcare facilities faced by those at the bottom of the pyramid due to conventional analysis and high costs. Key impact aspects include:

1. Equitable Healthcare Access: Sepsis-S solutions bridge gaps by reaching underserved-populations, providing timely-sepsis screening and AMR-surveillance conventional methods are impractical or costly.

2. Reduced Health Disparities: By eliminating barriers to entry, Sepsis-S contribute to reducing-health-disparities, ensuring that even the most vulnerable populations receive timely and effective healthcare services.

3. Resource Optimization: Sepsis-S is designed for simplicity and cost-effectiveness, optimizing resource utilization in low-resource regions to minimize the burden on healthcare systems.

4. Preservation of Antibiotics: By precisely identifying the causative agents, Sepsis-S aids in avoiding unnecessary and ineffective antibiotic use, Helps in antibiotic stewardship, critical in regions where resources for developing new drugs are scarce.

5. Alignment with Global Health Initiatives: Implementing Sepsis-S for AMR surveillance and sepsis management, aligns with global health initiatives, including the World Health Organization's efforts to address infectious diseases in low-resource settings. It contributes to the overall strengthening of healthcare infrastructure in resource-poor regions.

Our innovative solution, Sepsis-S, is poised to deliver impactful changes, benefiting various stakeholders:

1. Patients: Sepsis-S ensures rapid and precise diagnosis, translating into swift and effective treatment. For individuals facing sepsis, this means heightened chances of recovery and improved overall well-being.

2. Healthcare Providers: Sepsis-S streamlines diagnostic processes, equipping healthcare professionals with actionable insights in lesser time. Beyond individual patient care, this efficiency enhances resource allocation, easing the burden on healthcare facilities.

3. Communities in Resource-Poor Settings: Sepsis-S portability and user-friendly design bring advanced diagnostic capabilities to underserved regions. It empowers local healthcare providers to combat sepsis and antimicrobial resistance effectively, fostering health improvements in these communities.

4. Global Health Initiatives: Sepsis-S aligns seamlessly with global endeavors and contributes to achieving overarching health goals set by influential organizations like the WHO, fostering international collaborations.

5. Public Health: Through early detection and AMR surveillance, Sepsis-S helps in preserving antibiotic efficacy; contributes in global battle against antimicrobial resistance, safeguarding public health on global scale.

Sepsis-S is not merely a technological advancement; it's a transformative force with the potential to elevate patient outcomes, empower healthcare providers, address health inequalities, and play a pivotal role in shaping the trajectory of global public health.

At FastSense Innovations, our journey began with a deeply personal experience. Our founder, driven by the loss of her mother to pancreatic cancer, embarked on a mission to broaden her impact and serve society. This pivotal moment ignited a passion for leveraging scientific advancements to improve healthcare access, particularly for those in resource-constrained regions and LMICs.

Motivated by the desire to bring about social good through scientific innovation, our team is driven by a shared commitment to make a meaningful difference in people's lives. We recognize the urgent need to address healthcare disparities and ensure that life-saving technologies are accessible to all, regardless of geographic or economic barriers.

With this ethos at our core, FastSense Innovations was established as a for-profit company with a clear social mission. We believe that by harnessing the power of innovation and technology, we can revolutionize healthcare delivery and positively impact the lives of millions around the world. Through our dedication, expertise, and unwavering commitment to social responsibility, we are well-positioned to deliver transformative solutions that address the most pressing healthcare challenges facing humanity. We recognize the importance of addressing healthcare challenges in low-resource settings. To achieve this, we're prioritizing the development and deployment of on-the-spot testing solutions in these regions first. These technologies will be particularly beneficial in remote regions of Low- and Middle-Income Countries (LMICs) and other developing nations, where access to healthcare resources is limited. By working hand-in-hand with local communities and healthcare providers, we aim to make significant strides in improving healthcare accessibility and outcomes for all.

Following the successful development of a prototype for an AI-based solution for sepsis detection, doctors and healthcare professionals have given their approval and expressed keen interest in the product. Drawing from their feedback and our experiences during the prototype development phase, we are now poised to enhance the solution further. By closely aligning with the requirements outlined and incorporating insights gained from the prototype development process, we aim to refine the product to better meet the needs of healthcare professionals and patients. This iterative approach ensures that the final solution will be robust, effective, and well-suited to the challenges of sepsis detection in clinical settings.

Utilizing networking opportunities, awards, and mentorship platforms, we can engage in discussions and leverage technology to broaden our reach to a wider communities. Improved network access will facilitate broader outreach, allowing us to connect with a large no of people in need of our solution. LMICs and developing areas, many lack adequate healthcare access. When healthcare is out of reach financially or geographically, it profoundly impacts well-being. Neonatal sepsis emerges as a significant contributor to infant mortality rates worldwide, underscoring the critical demand for accessible and cost-effective healthcare interventions.

We believe that the support from Solve will be instrumental in overcoming challenges related to fundraising, regulatory hurdles, and risks. This backing will enable us to navigate seamlessly, bringing our solution to the market within the stipulated time frame. Solve not only helps us overcome the market entry barrier but also provides invaluable networking opportunities and mentoring, contributing to our long-term success.

"Innovation doesn’t equal social good, but social good can be accelerated by innovation… provided that purpose is at the heart of that innovation. ” We are into healthcare a booming sector in our country and globally.

This proposal outlines our innovative approach to scaling up our prior efforts in neonatal sepsis detection. We plan to achieve early detection of sepsis by developing a portable diagnostic kit equipped with smartphone-based software, facilitating easy transfer of results via phone. Unlike conventional lateral flow assays, our kit provides a concentration of analytes in numeric units, enabling direct interpretation. Furthermore, it requires a small sample volume, reducing the burden on healthcare providers and caregivers. Importantly, our solution fills a gap in areas lacking proper medical facilities and pathology labs, offering a user-friendly, on-chip sensor system with  multianalyte detection—a first-of-its-kind innovation. One of the advantages of our AI-enabled on-chip sensor system is its ability to provide real-time monitoring. Whether it's continuously monitoring a patient's vital signs,  the system can quickly detect changes and provide immediate feedback or alerts.

Our solutions are especially crafted keeping in mind the specific needs of LMICs and we merged it with AL/ML to come up with a robust platform solving the healthcare issues in these regions. Our solutions advocates that healthcare is a right for all not a privilege for few and aligned with WHO SDGs of health and well being for all and right to equality.  

Our groundbreaking solution, Sepsis-S, promises to revolutionize healthcare delivery, bringing about significant benefits for diverse stakeholders. Sepsis-S ensures rapid and accurate diagnosis, leading to prompt and effective treatment. This translates into higher chances of recovery and improved overall health for individuals battling sepsis. By streamlining diagnostic procedures, Sepsis-S provides healthcare professionals with actionable insights in less time. This efficiency not only improves individual patient care but also optimizes resource allocation, easing the strain on healthcare facilities. Sepsis-S's portability and user-friendly design make advanced diagnostics accessible in resource-limited regions. It empowers local healthcare providers to effectively combat sepsis and antimicrobial resistance, promoting health equity and well-being in these areas. Sepsis-S aligns seamlessly with global health initiatives, contributing to the attainment of overarching health objectives set by organizations like the WHO. It fosters international collaboration and strengthens efforts to combat antimicrobial resistance on a global scale. Through early detection and surveillance of antimicrobial resistance, Sepsis-S plays a vital role in preserving antibiotic efficacy and safeguarding public health worldwide. Sepsis-S represents more than just a technological advancement, it embodies a transformative force capable of improving patient outcomes, empowering healthcare providers, addressing health disparities, and shaping the future of global public health. An AI-powered solution grants entry to underserved areas and diverse communities, providing them with immediate access to a detection and screening tool for identifying sepsis on the spot.

Following indicators tells the success and impact for Sepsis-S:

Clinical Outcomes:

i. Reduction in sepsis-related mortality rates.

We  will track the mortality rates before and after the implementation of Sepsis-S in healthcare facilities to assess the reduction in sepsis-related deaths.

ii. Timeliness of Diagnosis: Decrease in the time taken for sepsis diagnosis.

We will measure the average time from the initial presentation of symptoms to the administration of targeted treatments. If implementation of Sepsis-S leads to reduction in diagnostic time will be the impact of our solution. 

iii. Antimicrobial Stewardship: Reduction in inappropriate antibiotic prescriptions.

The percentage of cases where antibiotics were prescribed appropriately based on the diagnostic results will indicate success of our solution. 

Accessibility and Inclusivity:

 The percentage increase in the screening of patients from resource-poor regions or vulnerable populations will indicate our impact.

Geographic Reach:

The number of new regions or facilities where Sepsis-S has been introduced is one of the success criteria.

 Patient Satisfaction: 

Positive feedback on the perceived effectiveness, ease of use, and overall satisfaction with Sepsis-S indicates our success. 

We-will regularly review and analyze this data to refine the solution and demonstrate its efficacy in improving sepsis management and AMR surveillance.

Our solution is well align with WHO SDG goals and we are committed to solve the pressing healthcare needs globally especially for LMICs

1. Our AI enabled solution offers point-of-care screening test, featuring a user-friendly app for seamless data storage and sharing with doctors from any location.
2. Analyte concentrations are provided in numerical units, allowing for straightforward interpretation, unlike lateral flow assays.
3. Operating on a single platform, our device delivers information on multiple analytes, rendering it cost-effective at USD 3-4 per test and significantly faster with results available in just 30 minutes compared to traditional lab-based assays, which take 1-2 days. Additionally, tests can be conducted at the patient's location, eliminating the need for sample transportation, expediting data analysis, enabling timely treatment, and reducing test costs.
4. Engineered for durability, our devices are adaptable to various climatic conditions, facilitating easy operation in rural and remote areas, where PHCs and ASHA workers with minimal training can administer the tests.
5. With minimal sample requirements, merely a prick is sufficient compared to conventional lab-based assays, and no specialized training is necessary. This feature not only minimizes discomfort for neonates but also streamlines testing for pimary care centers in resource constrained regions.
6. Our assay offers insights into causative agents, a unique feature not found in other assays. Timely identification of microbes enables targeted therapy,

Full time -3, Part time 7

Our team is supported by a robust network of scientific advisors, seasoned doctors, and experienced industrialists who are established leaders in product development within their respective fields

Over the past two years, our focus has been on addressing the critical issue of neonatal sepsis. With the alarming rate of infant mortality attributed to this condition, there's an urgent need for effective screening measures. Our AI-powered screening platform emerges as the comprehensive solution, offering early detection capabilities. By swiftly identifying potential cases, it equips healthcare professionals with the necessary information to accurately diagnose and initiate treatment promptly, thus significantly improving outcomes for newborns at risk of sepsis.

Ensuring diversity, minimizing barriers to opportunity, and fostering inclusivity are paramount values within our team. We employ various strategies to achieve these goals and cultivate a welcoming environment for all team members. Our team is having diverse backgrounds and experiences. By embracing a diverse workforce, we enrich our team with a wide range of perspectives, ideas, and talents, which ultimately enhances our creativity and innovation. Moreover, we implement inclusive policies and practices that aim to minimize barriers to opportunity for all staff members. This includes providing equal access to opportunities, professional development programs, and resources for skill enhancement. We strive to create a level playing field where individuals can thrive based on their merit and contributions, regardless of their background or identity. In addition, we prioritize creating a welcoming and inclusive environment where every team member feels valued, respected, and empowered to contribute their best work. This involves promoting open communication, active listening, and mutual respect among team members. We encourage collaboration and teamwork, recognizing that diverse perspectives lead to better decision-making and problem-solving.

Business Plan and Commercialization Strategy for Sepsis Point-of-Care Device: 

Executive Summary: FastSense Innovations is poised to revolutionize healthcare with our innovative Sepsis Point-of-Care Device. Our platform offers rapid and accurate sepsis detection at the bedside, addressing a critical need for timely intervention in one of the leading causes of mortality worldwide. With a focus on accessibility, affordability, and ease of use, our business plan outlines a strategic approach to commercialize our Sepsis Point-of-Care Device and drive widespread adoption across healthcare settings.

Market Analysis: The global sepsis diagnostics market is rapidly expanding, driven by the rising prevalence of sepsis and the increasing demand for rapid diagnostic solutions. With an estimated market size of 10 billion USD by 2025, there is a significant opportunity for growth and innovation in this space. Our Sepsis Point-of-Care Device targets hospitals, clinics, and emergency departments, where rapid sepsis diagnosis is critical for improving patient outcomes and reducing healthcare costs.

Product Overview: Our Sepsis Point-of-Care Device is a compact and user-friendly platform that enables rapid detection of sepsis biomarkers directly from a patient's blood sample. Leveraging advanced immunoassay technology and proprietary algorithms, our device delivers accurate results in minutes, enabling healthcare providers to initiate timely interventions and optimize patient care.

Commercialization Strategy:

1. Market Segmentation: Identify key target markets and customer segments, including hospitals, clinics, and emergency departments, with a focus on high-need areas with limited access to laboratory facilities.
2. Pricing Strategy: Implement a competitive pricing strategy that balances affordability with profitability, offering flexible pricing models and discounts for volume purchases.
3. Distribution Channels: Establish strategic partnerships with distributors and channel partners to facilitate market penetration and reach healthcare providers globally.
4. Marketing and Promotion: Develop targeted marketing campaigns to raise awareness of our Sepsis Point-of-Care Device among healthcare professionals, administrators, and stakeholders. Utilize digital marketing, industry conferences, and thought leadership content to showcase the benefits and value proposition of our platform.
5. Regulatory Compliance: Obtain necessary regulatory approvals and certifications in target markets to ensure compliance with local regulations and standards governing medical devices and healthcare practices.
6. Training and Support: Provide comprehensive training programs and ongoing technical support to healthcare providers and end-users to ensure proficiency in using our Sepsis Point-of-Care Device and maximize adoption.

Financial Projections: Based on market analysis and sales forecasts, we project steady revenue growth over the next five years, with potential for expansion into additional markets and applications. Our financial projections are conservative yet optimistic, reflecting our confidence in the market demand for our Sepsis Point-of-Care Device and our ability to execute on our commercialization strategy

FastSense Innovations is poised to disrupt the sepsis diagnostics market with our Sepsis Point-of-Care Device, offering a game-changing solution for rapid and accurate sepsis detection. With a strategic focus on accessibility, affordability, and ease of use, we are committed to driving widespread adoption of our platform and improving patient outcomes globally.

Our plan for achieving financial sustainability revolves around a multi-faceted approach that encompasses revenue generation, strategic partnerships, and cost optimization. Firstly, we aim to generate revenue through the sale of our point-of-care sepsis management and AMR surveillance tool, targeting both healthcare facilities in LMICs and regions with high incidences of sepsis. Additionally, we plan to explore licensing opportunities and subscription-based models to diversify our revenue streams. We have our customizable software platform that we can explore for other applications and can be a revenue source for us.  

Furthermore, strategic partnerships with healthcare organizations, governmental agencies, and non-profit entities will allow us to expand our reach and access new markets. Collaborations with research institutions and universities will also facilitate ongoing innovation and product development, enhancing our competitive advantage.

Cost optimization strategies, including efficient resource allocation, lean operations, and prudent financial management, will ensure that we maintain a healthy bottom line while maximizing value for our stakeholders.

As evidence of our financial sustainability plan, we can provide metrics such as revenue growth, profit margins, customer retention rates, and successful fundraising rounds. Additionally, testimonials from satisfied customers, positive feedback from strategic partners, and recognition within the industry serve as indicators of our successful execution of this plan thus far.